Predicate |
Object |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
filingDate |
2010-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2013-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2013505934-A |
titleOfInvention |
Ophthalmic aqueous injectable composition and method of use |
abstract |
The present invention relates to providing an ophthalmic composition suitable for injection into the vitreous. The composition contains an amount of complexing agent in the eye that reacts with one or more endogenous components (eg, hyaluronic acid) to form a highly viscous mass. This mass can help create the desired release profile of the therapeutic agent. Generally, the complexing agent is supplied in an amount sufficient to form a highly viscous mass in the vitreous humor of the human eye when the composition is injected into the human eye. The highly viscous mass generally releases the therapeutic agent in the vitreous humor by disintegrating the mass and / or diffusing the therapeutic agent from the highly viscous mass. This is advantageous because the therapeutic agent can be released over a long period of time. |
priorityDate |
2009-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |